Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Tenofovir To Abacavir In HIV-1-Infected Subjects With Loss Of Bone Mineral Density

Trial Profile

Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Tenofovir To Abacavir In HIV-1-Infected Subjects With Loss Of Bone Mineral Density

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Mar 2015

At a glance

  • Drugs Abacavir (Primary) ; Antiretrovirals; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Emtricitabine; Emtricitabine/tenofovir disoproxil fumarate; HIV protease inhibitors; Lamivudine; Non-nucleoside reverse transcriptase inhibitors; Raltegravir; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Acronyms OsteoTDF; OSTEOTENOFOVIR
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Mar 2013 Interim results (n=48) presented at the 20th Conference on Retroviruses and Opportunistic Infections.
    • 03 Oct 2011 Planned End Date changed from 1 Dec 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top